Cardioprotective effects of alpha‐mangostin on doxorubicin‐induced cardiotoxicity in rats
2022
Eisvand, Farhad | Imenshahidi, Mohsen | Ghasemzadeh Rahbardar, Mahboobeh | Tabatabaei Yazdi, Seyed Abbas | Rameshrad, Maryam | Razavi, Bibi Marjan | Hosseinzadeh, Hossein
The main adverse effect of doxorubicin is cardiotoxicity. Oxidative stress and apoptosis induction have been suggested as mechanisms involved in its cardiotoxicity. In this study, cardioprotective effects of alpha‐mangostin against doxorubicin‐induced cardiotoxicity have been investigated in rats. Forty‐two rats were divided as follows: Control, doxorubicin (2 mg/kg every 48 hr), alpha‐mangostin (200 mg/kg), alpha‐mangostin (50, 100, 200 mg/kg) + doxorubicin (2 mg/kg every 48 hr), and vitamin E (200 IU/kg) + doxorubicin (2 mg/kg every 48 hr). Alpha‐mangostin was administered by gavage for 19 days, while doxorubicin (12 days) and vitamin E (19 days) were injected intraperitoneally. Doxorubicin decreased heart rate, increased electrocardiogram signal components duration and reduced systolic and diastolic arterial blood pressure, and caused histological damage in the heart of rats. Doxorubicin decreased heart weight and heart/body weight ratio, as well as elevated creatine phosphokinase isoenzyme and lactate dehydrogenase. Doxorubicin increased malondialdehyde, inflammatory biomarkers, and caspases 3 and 9 and decreased reduced glutathione content in heart tissue but co‐administration of alpha‐mangostin (100 mg/kg) restored all doxorubicin toxic effects. Results show that alpha‐mangostin has protective effects against doxorubicin‐induced cardiotoxicity by antioxidant, antiinflammatory, and antiapoptotic effects that may ameliorate doxorubicin cardiotoxicity in human chemotherapy without reduction in its anticancer effect.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by National Agricultural Library